Lupin Limited disclosed an independent Environmental, Social and Governance (ESG) rating of 60, placing the company in the 'Adequate' category. The disclosure was made on August 24, 2026.

The rating was assigned by ESG Risk Assessments & Insights Limited. The firm prepared the report independently using data available in the public domain. Lupin did not engage the agency for this specific assessment.

Disclosure Details

The company issued the disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Amit Kumar Gupta, Company Secretary & Compliance Officer, signed the communication.

Lupin Limited has entered into an exclusive licensing agreement with Visus Therapeutics for Yuvezi (YuveziTM) covering the European market. The deal carries total potential payments of up to €75 million, structured as a combination of strategic funds and milestone payouts.

Deal highlights

The key parameters of the agreement are outlined below:

The agreement grants Lupin exclusive rights to commercialise Yuvezi across Europe, with the total consideration contingent on the achievement of defined milestones in addition to the upfront strategic component.

Expanded territory and structure

The agreement, signed on August 20, 2026, expands the licensed territories beyond the initial European scope to include the United Kingdom, Switzerland, Norway, and Iceland. VISUfarma B.V., a wholly owned subsidiary of Lupin, holds the exclusive rights to undertake regulatory activities, commercialization, marketing, promotion, distribution, and sale of Yuvezi in these regions.

The financial structure comprises two main components:

• A €20 million strategic investment in the capital stock of Visus or its parent entity through a SAFE (Simple Agreement for Future Equity) instrument.
• Up to €55 million in regulatory and commercial milestone payments.

Additionally, the agreement provides for royalty payments based on net sales and sales milestone payments upon achievement of specified sales thresholds in the licensed territories.

Strategic rationale

This partnership strengthens Lupin's ophthalmology portfolio and expands its Specialty Business presence. Yuvezi is indicated for the treatment of presbyopia in adults. The addition of this asset supports Lupin's strategy for expanding its specialty care business through innovative therapies that address significant unmet patient needs in the aging eye segment.